



**RUTGERS
HEALTH**

**Research Report
FY24**



TABLE OF CONTENTS

	PAGE
Introduction	1
By the Numbers	2
Research Award Highlights	3
Publication Highlights	5
Research Training	6
Advancing Inclusive Excellence	6
Honors and Recognitions External	7
Honors and Recognitions Internal	8
Research Business Development	9
Tech Transfer and New Ventures	9
Research Resources	10
Research Facilities Updates	11
Philanthropy	11
Our Team	12

INTRODUCTION

Dear Colleagues,

We are pleased to share a snapshot of the Rutgers Health research activities for fiscal year 2024 (FY24). After a decade of exceptional achievements, Rutgers Biomedical and Health Sciences (RBHS) announced that it will be known as Rutgers Health. Our discoveries and innovation have had a positive impact on the health of New Jersey and society at-large, evidenced in part by Rutgers leadership in the area of COVID testing and treatments.

Over the past decade, our research portfolio has increased by 2.6-fold from \$218 million in FY14 to \$564 million in FY24. This remarkable growth reflects the hard work, passion, and dedication of our research community and the impact of their work across diverse fields of health sciences.

In FY24, Rutgers Health continues to build on many individual and team successes. Included among these is the renewal of four major National Institutes of Health (NIH) awards that support premier Rutgers Health schools, centers, and institutes. Two of these awards support the Cancer Institute of New Jersey and the Rutgers Health-based New Jersey Alliance for Clinical and Translational Science. Notably, Rutgers Health is one of only 46 institutions in the US that has received both of these major awards, translating into tangible health improvements for our patients and communities. The Rutgers Institute for Nicotine & Tobacco Studies (formerly the Rutgers Health Center for Tobacco Studies) recently received \$7.3 million to study tobacco disinformation. Also, the Environmental and Occupational Health Sciences Institute center grant was renewed for five years and is now in its remarkable 37th consecutive year of NIH funding!

Research education and training has also been enhanced over recent years. One noteworthy example is the Learning Health System Embedded Scientist Training and Research (LHS E-STaR) Center, funded by the Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI), that will train future scientists and health professionals to evaluate and improve the quality, outcomes, and patient-centeredness of care through educational classes, mentoring, and hands-on learning. Rutgers Health--together with our partner RWJBarnabas Health--rolled out the Rutgers Clinical and Research Data Warehouse, a secure, HIPAA-compliant central repository that includes diverse health care data and essential analytical tools for gaining a new perspective on medical conditions, outcomes, and treatments. This invaluable resource for our researchers, clinicians, and health care professionals provides access to aggregated and organized robust clinical data to generate potentially life-saving insights. Our expert clinical trial investigators have continued to expand the opportunities for our patients to engage in promising clinical trials, offering in FY24 a total of 347 new and 640 actively recruiting trials in many disease areas (compared with 333 and 544, respectively, for FY23).

As we look to the future, our commitment to advancing research and innovation remains at the forefront of our academic mission. Our work continues to be guided by the core values of respect, collaboration, inclusion, excellence, innovation, and accountability, as articulated in the RBHS/Rutgers Health strategic plan. These principles ensure that our research makes a meaningful impact, from the laboratory bench to the communities we serve. We are honored to continue this important work together, and are excited to see how our collective efforts will advance health through research and innovation in the coming year and beyond.

*Kathleen W. Scotto, PhD
Vice Chancellor for Research
and Research Training*



*M. Bishr Omary, MD, PhD
Senior Vice Chancellor for
Academic Affairs and Research*




*Brian L. Strom, MD, MPH
Chancellor and Executive
Vice President of Health Affairs*




BY THE NUMBERS

**Sponsored Research Awards
FY20 – FY24**



**Number of Clinical Trials
FY23 – FY24***



*In a given FY, some 'new' trials may turn to 'actively recruiting'

FY24

\$289M
(\$277M)
**Total
Federal**

\$213M
(\$221M)
NIH

\$128M
(\$120M)
State

\$120M
(\$121M)
Corporate

\$27M
(\$30M)
Other

3,148
(3,299)
Publications

Training Awards
NIH \$12M
(\$8M)
Non-NIH \$9M
(\$3M)

72
(81)
Disclosures

49
(71)
**Patents
Issued**

Enrolled
514 MS
(588)
298 PhD
(352)

244
(204)
Post-docs

20
(18)
**License and
Option
Agreements**

\$7M
(\$8M)
**Licensing
Revenue**

FY23 numbers are shown in parentheses

RESEARCH AWARD HIGHLIGHTS

RESEARCH CENTERS

RUTGERS INSTITUTE FOR TRANSLATIONAL MEDICINE AND SCIENCE

Reynold Panettieri received \$39.6 million over 7 years from the NIH to advance clinical and translational science through the New Jersey Alliance For Clinical and Translational Science (NJ ACTS), with the goal of enhancing infrastructure to rapidly translate research into patient care.



Shawna Hudson and **Ethan Halm** received \$4.2 million over 5 years from the Agency for Healthcare Research and Quality to establish the Learning Health System Scientist Training and Research Center (LHS STAR) in NJ.



NEW JERSEY MEDICAL SCHOOL

David Alland received \$20.8 million over 5 years from the NIH to enhance research and biothreat response capabilities at the Rutgers University Regional Biocontainment Laboratory (RBL) to improve facilities, support BSL-3 practices, and develop animal disease models and associated services.



CANCER INSTITUTE OF NEW JERSEY

Steven Libutti received \$17.5 million over 5 years from the NIH to maintain the National Cancer Institute (NCI) Comprehensive Cancer Center (CCC) designation for Rutgers Cancer Institute of New Jersey (CINJ), in recognition of significant growth in research, clinical care, and community outreach.




Antoinette Stroup received \$6.3 million from over 3 years from the NJ Department of Health to maintain the NJ State Cancer Registry (NJSCR) and to use its data to conduct epidemiologic studies on cancer in New Jersey,



ROBERT WOOD JOHNSON MEDICAL SCHOOL

Zhiping Pang, Jubao Duan (University of Chicago), and **Jennifer Mulle** received \$8.7 million over 5 years from the NIH to establish the Assay and Data Generation Center (ADGC) for the model of induced pluripotent stem cell (iPSC)-derived neurons for neurodevelopmental and psychiatric disorders.



INSTITUTE FOR HEALTH, HEALTH CARE POLICY AND AGING RESEARCH

William Hu and Bei Wu (New York University) received \$3.5 million over 5 years from the NIH to establish a resource center to address health disparities in Alzheimer's and related dementias among Asian and Pacific Americans through research, mentoring, and community engagement.



RESEARCH PROJECTS

NEW JERSEY MEDICAL SCHOOL

David Alland received \$3.8 million over 5 years from the NIH to develop tests for detecting genetic mutations responsible for resistance to new tuberculosis (TB) drugs using an innovative fluidic approach.



Amariliz Rivera, **William Gause**, and **Mark Siracusa** received \$3.8 million over 5 years from the NIH to study alveolar macrophage function in lung infections, and how past exposures affect tissue repair and lung health.



Yosuke Kumamoto received \$3.6 million over 5 years from the NIH to study dendritic cell differentiation to identify therapeutic targets for type 2 inflammation-related diseases like allergies.

David Alland received \$3.4 million over 5 years from the NIH to develop a rapid, sensitive point-of-care test using nanoreactor bead chemistry and digital multiplex assays to detect clinically relevant forms of drug resistance in TB.

Displayed pictures are of contact PI

Yingda Xie received \$3.3 million over 5 years from the NIH to develop imaging tools for early TB detection in asymptomatic individuals to improve diagnosis and prevention.



ERNEST MARIO SCHOOL OF PHARMACY

Jun Wang received \$3.7 million over 5 years from the NIH to develop broad-spectrum antivirals targeting enterovirus proteins and to test their efficacy in mouse models.



INSTITUTE FOR HEALTH, HEALTH CARE POLICY AND AGING RESEARCH

Stephen Crystal received \$3.5 million over 5 years from the NIH to improve pre-release medication for opioid use disorders and peer navigation in NJ state prisons, aiming to enhance re-entry outcomes for individuals with substance use disorders.



Tammy Chung received \$3.5 million over 5 years from the NIH to study acute and long-term effects of cannabis on psychomotor performance and therapeutic outcomes in chronic pain and anxiety.



CANCER INSTITUTE OF NEW JERSEY

Katie Recuay received \$3.3 million over 5 years from the NIH to evaluate the 'Managing Your Health' intervention for enhancing follow-up care and self-management in young adult survivors of childhood cancer.



INSTITUTE FOR NICOTINE AND TOBACCO STUDIES

Kymberle Sterling and **Andrea Villanti** received \$3.2 million over 5 years from the NIH to assess anti-disinformation messages countering misinformation about the Food and Drug Administration's (FDA) proposed menthol cigarette and flavored cigar ban in African American communities.



ENVIRONMENTAL AND OCCUPATIONAL HEALTH SCIENCES INSTITUTE

Emily Barrett, Martin Blaser, Maria Dominguez-Bello (Rutgers New Brunswick), **Daniel Horton, Manuel Jimenez,** and **Kristy Palomares** (Saint Peter's University Hospital) received \$3.1 million over 2 years from the NIH to explore how early life microbiome disruptions affect airway health and asthma disparities in pregnant individuals.



CLINICAL TRIALS

CANCER INSTITUTE OF NEW JERSEY

Matthew Matasar received \$6.4 million over 5 years from Merck Sharp & Dohme LLC to assess the efficacy and safety of a combined antibody therapy compared to standard chemotherapy in patients with Hodgkin Lymphoma.



Joanna Rhodes received \$3.8 million over 5 years from the BeiGene Switzerland GmbH to compare the efficacy of two combination therapies in treating previously untreated chronic lymphocytic leukemia.



Biren Saraiya received \$3.2 million over 5 years from Merck & Company Inc. to compare an oral inhibitor to hormonal therapies for advanced prostate cancer.



EQUIPMENT

RUTGERS SCHOOL OF NURSING

Linda Flynn received \$950,650 over 3 years from the Health Resource and Services Administration (HRSA) to expand simulated clinical learning exercises and programs.



NEW JERSEY MEDICAL SCHOOL

Jason Weinstein received \$340,650 from the NIH to acquire an Akoya Phenocycler Fusion imaging system for advanced multiplex imaging of up to 60 biomarkers in tissue samples.



PUBLICATION HIGHLIGHTS*

Jeffrey L Carson, Maria Mori Brooks, Paul C Hébert, Shaun G Goodman, Marnie Bertolet, ..., Benoit Lattuca, Harvey D White, Sheryl F Kelsey, P Gabriel Steg, John H Alexander; MINT Investigators. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia. **N Engl J Med** 2023

Jeffrey L Carson, Simon J Stanworth, Gordon Guyatt, Stacey Valentine, Jane Dennis, ..., Cynthia So-Osman, Jonathan Waters, Erica M Wood, Nicole D Zantek, Monica B Pagano. Red Blood Cell Transfusion: 2023 AABB International Guidelines. **JAMA** 2023

Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, ..., Raoul Tibes, Aristotelis Tsirigos, Michael Andreeff, Eviropidis Gavathiotis, Iannis Aifantis. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. **Cancer Discov** 2023

Mackenzie Henderson, Daniel B Horton, Vikram Bhise, Gian Pal, Greta Bushnell, Chintan V Dave. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among Us Adults and Children, 2001 Through 2020. **JAMA Neurol** 2023

Keith S Kaye, Andrew F Shorr, Richard G Wunderink, Bin Du, Gabrielle E Poirier, ..., Lan Chen, Harald Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac. Efficacy And Safety of Sulbactam-Durlobactam Versus Colistin for the Treatment of Patients with Serious Infections Caused by Acinetobacter Baumannii-Calcoaceticus Complex: A Multicentre, Randomised, Active-Controlled, Phase 3, Non-Inferiority Clinical Trial (ATTACK). **Lancet Infect Dis** 2023

Nina A Cooperman, Shou-En Lu, Adam W Hanley, Thanusha Puvananayagam, Patricia Dooley-Budsock, Anna Kline, Eric L Garland. Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain: A Randomized Clinical Trial. **JAMA Psychiatry** 2024

Ian Antón Oldenburg, William D Hendricks, Gregory Handy, Kiarash Shamardani, Hayley A Bounds, Brent Doiron, Hillel Adesnik. The Logic of Recurrent Circuits in the Primary Visual Cortex. **Nat Neurosci** 2024

Partho P Sengupta, Jolanda Kluin, Seung-Pyo Lee, Jae K Oh, Anthal I P M Smits. The Future of Valvular Heart Disease Assessment and Therapy. **Lancet** 2024

Elizabeth A Suarez, Brian T Bateman, Sonia Hernandez-Diaz, Loreen Straub, Christopher J McDougale, Katherine L Wisner, Kathryn J Gray, Page B Pennell, Barry Lester, Yanmin Zhu, Helen Mogun, Krista F Huybrechts. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. **JAMA Psychiatry** 2024

Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, Prakash Jadhav, Haozhou Tan, Kan Li, Ashima Chopra, Alexandra Ford, Xiang Chi, Francesc Xavier Ruiz, Eddy Arnold, Xufang Deng, Jun Wang. Design of A SARS-Cov-2 Papain-Like Protease Inhibitor with Antiviral Efficacy in a Mouse Model. **Science** 2024

Yingda L Xie, Christie Eichberg, Nchimunya Hapeela, Elizabeth Nakabugo, Irene Anyango, ..., Moses L Joloba, Samuel G Schumacher, Kimberly D McCarthy, Lydia Nakiyingi, Susan E Dorman. Xpert MTB/RIF Ultra Versus Mycobacterial Growth Indicator Tube Liquid Culture for Detection of Mycobacterium Tuberculosis in Symptomatic Adults: A Diagnostic Accuracy Study. **Lancet Microbe** 2024

*Includes original research articles and guideline publications from the top 135 journals listed by the 2023 Science Citation Index (SCI) with first and/or last author(s) affiliated with with RBHS/Rutgers Health [2023 journal impact factor of 20.3 or more].

RESEARCH TRAINING

K12 Award (NIH): Institutional Research and Academic Career Development Award (IRACDA) INSPIRE Biomedical Research and Education Training Postdoctoral Program

Martha Soto and Gary Brewer, Robert Wood Johnson Medical School

The Rutgers INSPIRE Program offers mentorship in research, educational training, and teaching support to cultivate future scientist-educators and inspire underrepresented undergraduates to pursue biomedical careers.



T32 Award (NIH): Training in Addiction Research Program

Christopher Pierce, Robert Wood Johnson Medical School

The Rutgers Training Program in Addiction Research (TARP) aims to unify substance use disorder research training by leveraging strengths in basic and imaging research. It provides diverse predoctoral and postdoctoral researchers with interdisciplinary training in addiction neuroscience.



Health Resources and Services Administration (HRSA) Award: Culturally and Linguistically Appropriate Student Training Program (CLAST)

Ana Natale-Pereira, New Jersey Medical School

The NJMS CLAST program aims to improve health care for Limited English Proficiency (LEP) patients in NJ by enhancing access to quality care. The program will train medical students in culturally and linguistically appropriate care, developing skills through education and clinical experience.



ADVANCING INCLUSIVE EXCELLENCE

Rutgers Health is the first institution to receive the American Association for the Advancement of Science (AAAS) STEM Equity Achievement (SEA) Change Biomedicine Bronze Award, recognizing its commitment to advancing inclusive excellence in biomedical health sciences. This remarkable achievement was spearheaded by the efforts of **Sangeeta Lamba** and her dedicated team, who have been instrumental in leading this strategy. This accolade follows a comprehensive institutional review and a five-year action plan to improve diversity, faculty recruitment, and retention. The plan includes enhanced mentor training, leadership dialogue, and programs to support postdoctoral and clinical trainees. The SEA Change awards, which require re-evaluation every five years, underscore the institution's dedication to transformative change in the biomedical field.

Congratulations to Dr. Lamba and her team!



HONORS AND RECOGNITIONS | EXTERNAL

2023/2024 Elected Fellows of the American Association for the Advancement of Science (AAAS)



Gary Aston-Jones – Professor, Robert Wood Johnson Medical School; Director, Brain Health Institute



Maral Mouradian – Distinguished Professor, Robert Wood Johnson Medical School; Vice Chancellor for Faculty Development, Rutgers Health



Kathleen Scotto – Professor, Robert Wood Johnson Medical School; Vice Chancellor for Research and Research Training, Rutgers Health; Vice Dean, School of Graduate Studies

2024 Julius M. Friedenwald Medal, American Gastroenterological Association

Bishr Omary – Professor, Robert Wood Johnson Medical School and Center for Advanced Biotechnology and Medicine; Senior Vice Chancellor for Academic Affairs and Research, Rutgers Health



2024 American Chemical Society (ACS) Infectious Diseases/ACS Division of Biological Chemistry Young Investigator Award

Jun Wang – Associate Professor, Ernest Mario School of Pharmacy



2024 Edward J. III Excellence in Medicine, New Jersey Health Foundation

Physician's Award

Marc Klapholz – Professor, Rutgers New Jersey Medical School; Chair, Department of Medicine



Outstanding Scientist Award

Martin Blaser – Professor, Robert Wood Johnson Medical School; Director, Center for Advanced Biotechnology and Medicine



Matthew Neiditch – Professor, Rutgers New Jersey Medical School



2024 Searle Scholar

Ian Oldenburg – Assistant Professor, Robert Wood Johnson Medical School and Center for Advanced Biotechnology and Medicine



2024 Catherine Worthington Fellow (Research) Award, American Physical Therapy Association

Alma Merians – Professor, Rutgers School of Health Professions; Associate Dean, Strategic Initiatives and Interprofessional Education and Practice



2024 Society for the Study of Reproduction Virendra B. Mahesh New Investigator Award

Shuo Xiao – Associate Professor, Ernest Mario School of Pharmacy



2024 U.S. Young Ambassador for the NJ area by the American Society for Microbiology

Liisa Veerus – Postdoctoral fellow, Robert Wood Johnson Medical School and Center for Advanced Biotechnology and Medicine



2024 NIH Outstanding Scholars in Neuroscience Award

Andrew Boreland – PhD student, Rutgers School of Graduate Studies–Biomedical Health Sciences



HONORS AND RECOGNITIONS | INTERNAL

2023–2024 Rutgers University Faculty Year-End Excellence Award Recipients

Board of Trustees Research Fellowship for Scholarly Excellence

Shuo Xiao – Associate Professor, Ernest Mario School of Pharmacy

Board of Trustees Award for Excellence in Research

Emily Barrett – Professor, Rutgers School of Public Health and Environmental and Occupational Health Sciences Institute

Faculty Scholar-Teacher Award

Jaya Satagopan – Professor, Rutgers School of Public Health; Associate Dean, Faculty Affairs, Rutgers Health

Presidential Award for Excellence in Teaching

Marybec Griffin – Assistant Teaching Professor, Rutgers School of Public Health

2023 RBHS Chancellor Awards – Research Recognitions*

Excellence in Basic Sciences Research Award

Established Investigator

Ah-Ng Tony Kong – Distinguished Professor, Ernest Mario School of Pharmacy

Distinguished Innovator

James Guarrera – Professor, New Jersey Medical School; Executive Vice Chair, Department of Surgery

Excellence in Clinical or Health Sciences

Research Award

Early Career

Stephanie Shiau – Assistant Professor, Rutgers School of Public Health

Chintan Dave – Assistant Professor, Ernest Mario School of Pharmacy

Established Investigator

Olivia Wackowski – Associate Professor, Rutgers School of Public Health

Lifetime Distinguished Achievement Award

Alfred Tallia – Professor, Robert Wood Johnson Medical School; Chair, of the Department of Family Medicine and Community Health

2023-2024 Rutgers Service Recognition

Yingting Zhang – Research Services Librarian, RWJ Library of the Health Sciences, Adjunct Assistant Professor, Robert Wood Johnson Medical School

2024 School of Graduate Studies Community Engagement Award

Sean Stratton – PhD student, Rutgers School of Public Health

2024 Rutgers School of Graduate Studies Award for Excellence in Leadership and Teaching

Adriana Paldino – MS student, Rutgers School of Graduate Studies–Biomedical Health Sciences

2024 RBHS Chancellor Awards – Research Recognitions

Excellence in Basic Sciences Research Award

Early Career

Jian Cao – Assistant Professor, Robert Wood Johnson Medical School and Rutgers Cancer Institute

Established Investigator

Wei-Xing Zong – Professor, Ernest Mario School of Pharmacy, John L. Colaizzi Chair in Pharmacy

Subhajyoti De – Associate Professor, Rutgers Cancer Institute of New Jersey

Daniel Herranz – Associate Professor, Rutgers Cancer Institute of New Jersey

Excellence in Clinical or Health Sciences

Research Award

Early Career

Slawa Rokicki – Assistant Professor, Rutgers School of Public Health

Denalee O'Malley – Assistant Professor, Robert Wood Johnson Medical School

Established Investigator

Nina Cooperman – Associate Professor, Robert Wood Johnson Medical School

Lifetime Distinguished Achievement Award

Jeffrey D. Laskin – Distinguished Professor, School of Public Health; Director, Division of Toxicology at Environmental & Occupational Health Sciences Institute

Tamara Minko – Distinguished Professor, Ernest Mario School of Pharmacy; Chair, Department of Pharmaceutics

*For a full listing of the Chancellor awards, see:

<https://rutgershealth.org/chancellor/chancellor-awards>

RESEARCH BUSINESS DEVELOPMENT

The Rutgers Health Research Business Development unit fosters collaboration with industry partners to advance scientific discovery and improve human health through innovative solutions, research studies, and clinical trials. Notable industry collaboration projects in FY24 include:

Advil Pain Equity Project: Dr. Ying-Xian Pan collaborated with Haleon to develop a pain management course for medical students to ensure equitable access and address educational disparities. The course will be piloted at Morehouse School of Medicine with plans for implementation at RH.

New Jersey Center for Advancing Technology and Cardiovascular Health (NJ CATCH): Drs. Partho Sengupta and Naveena Yanamala spearheaded the NJ CATCH program, which integrates digital translational medicine and AI innovations to revolutionize cardiovascular care.

Liver Biobanking Study: Dr. Vinod Rustgi and Regeneron Pharmaceuticals advanced to the second phase of their study for liver diseases by analyzing patient and biomarker data.

IntelliGenes: Dr. Zeeshan Ahmed combined artificial intelligence and machine learning approaches to measure the significance of specific genomic biomarkers to help predict diseases in individuals.

Babies near Working Mothers in Baby Friendly Spaces (BFS): Drs. Gloria Bachmann and Maria Dominguez-Bello are exploring the benefits of infants being near their mothers at work, with significant interest from companies such as Johnson & Johnson and Kenvue.

Prostate Cancer Drug Resistance Research: Dr. Antonina Mitrofanova, in collaboration with Merck and small pharma, focused on extending the efficacy of prostate cancer treatments by understanding drug resistance mechanisms.

Parkinson's and Dementia with Lewy Bodies Research: Dr. Maral Mouradian leveraged innovative RNA-targeting technology to treat neurodegenerative diseases by reducing α -synuclein protein levels.

Implant Inflammation Research: Dr. George Kotsakis, funded by Straumann, explored innovative treatment protocols for peri-implantitis using osteogenerative biomaterials.

TECH TRANSFER AND NEW VENTURES

Luciano D'Adamio, a professor at NJMS and co-founder of **NanoNewron**, aims to advance the development of blood-brain barrier-permeable nanobodies designed to inhibit TNF α activity. These nanobodies target central nervous system diseases, including Alzheimer's disease, where supraphysiological TNF α has a pathogenic role.



Sergei Kotenko and **Ray Birge**, NJMS professors, founded **Targeron Therapeutics** with Rohinton Toddywala to advance the development of immunomodulators that boost host multipronged immune defenses against viral infection and cancer at the disease sites.

Renata Pasqualini and **Wadih Arap**, professors at NJMS, resident faculty at the Rutgers Cancer Institute of New Jersey, and co-founders of **MBrace Therapeutics**, have secured \$85 million in Series B funding to advance the clinical development of antibody-drug conjugates for oncology applications.



Mark Siracusa, an associate professor at NJMS, founder and president of **NemaGen Discoveries** has secured \$1 million from the Foundation Venture Capital Group, supplemented by Small Business Innovation Research grants, to develop therapies for allergic inflammation and mast cell disorders.

RESEARCH RESOURCES

Rutgers Health offers a variety of resources to support research and advance medical studies. Highlighted below are three resources demonstrating Rutgers Health's commitment to research excellence.

Rutgers Clinical and Research Data Warehouse (CRDW)

Rutgers Health and RWJBarnabas Health have collaborated to establish the Rutgers Clinical and Research Data Warehouse (CRDW). The Warehouse facilitates the automated collection of data from multiple sources, including Electronic Medical Records (EMRs), Tumor Registries, Biospecimen Repositories, and various imaging and genomics repositories. The first-generation CRDW was developed at Rutgers Cancer Institute of New Jersey with a focus on precision oncology. It now serves as an enterprise-wide resource, housing data across medical specialties in a secure, HIPAA-compliant environment managed by Rutgers Office of Advanced Research Computing within the Office of Information Technology. To learn more about the CRDW, including details on fees and benefits, please visit the Rutgers CRDW website. For questions, please email crdw_requests@oarc.rutgers.edu.



Rutgers Institute for Health, Health Care Policy and Aging Research Survey/Data Core

Rutgers Institute for Health (IFH) houses the IFH Survey/Data Core, a NIH-compliant core facility that provides researchers with access to specialized survey data and multiple large electronic healthcare databases. The Core maintains state, national, and international healthcare and administrative databases for research, including the Integrated Population Health Data (iPHD) Project, Medicare, Medicaid, MarketScan, and Clinical Practice Research Datalink (CPRD Gold and Aurum).

The Core, which operates within the CRDW, also offers a wealth of survey data from multiple projects and provides access to the ADHI platform—a versatile, fully customizable, web-based survey platform designed for conducting prospective research with diverse, multilingual, and difficult-to-reach populations. Trained research staff are available to offer efficient data management and analytic support to users. Investigators and teams interested in learning more about the resources available through the IFH Survey/Data Core can inquire for more details: <https://ifhcore.rutgers.edu/contact-us>.

Research Data Services at the Health Sciences Libraries

The Rutgers Health Librarians are available to assist you in navigating the complex landscape of research data management. Here's how they can help:

- Consultation on compliance with NIH Data Management and Sharing Policy.
- Workshops on using DMPTool to develop data management plans for NIH proposals.
- Assistance in identifying appropriate data repositories.
- Instruction on best practices of effective data visualization.
- Support on data literacy.

For more information, please email rbhs_librarians@libraries.rutgers.edu



RESEARCH FACILITIES UPDATES

The **Rutgers Health Building (RHB)** at the **HELIX**, with a new Nokia Bell Labs building immediately adjacent, will be a 13-story building that spans 573,000 square feet (sq ft). It includes open social space (floor 1) that houses retail and a market hall, research spaces that include 60 wet and 20 dry labs on three floors (floors 2-4; with 80,000 sq ft of assignable space), and research and building support including autoclaves and glass washers (basement), and a vivarium (floor 12). The remaining floors of the RHB include medical school classroom and office space (floors 5-8), and an innovation hub that will be shared between Rutgers, RWJBarnabas Health, and other NJ institutions (floors 9-11). The research floors also include meeting rooms, kitchens and additional common areas. The RHB \$732 million endeavor is beginning to take shape for passersby and is slated for completion and occupancy during the Fall of 2026.



The **Jack and Sheryl Morris Cancer Center**, opening in early 2025, will be NJ's first freestanding cancer hospital, integrating research, prevention, and clinical care in a state-of-the-art, 12-story, 510,000-square-foot facility. Developed by RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, the \$750 million center will offer comprehensive oncology services, including advanced imaging, radiation therapy, chemotherapy, and surgical treatments. It will also

feature on-site laboratories for cutting-edge research, enhancing patient treatment personalization. This center is part of a broader initiative to create an integrated network of advanced cancer care facilities in NJ.

PHILANTHROPY

Philanthropic contributions to Rutgers Health research priorities totaled \$17.6 million for FY24. Rutgers Health benefits from substantial foundation and corporate support for research, including significant funding from the American Cancer Society, which has backed Rutgers University's research priorities for more than seventy years. Notably, Parker Health Group has contributed \$18.8 million to establish the Parker Health Group Division of Geriatrics at Robert Wood Johnson Medical School. This division aims to advance care for seniors through research, education, and interdisciplinary collaboration, addressing the increasing needs of America's aging population. Another significant highlight this year was the establishment of the William Hait Endowed Directorship at Rutgers Cancer Institute of New Jersey, named after its founding director. This directorship fund, created with over \$6 million from generous donors, will support innovative research endeavors across the institute, advancing basic science and new cancer treatments. If you would like to support Rutgers Health research, please consider making a donation: <https://give.rutgersfoundation.org/health/research-innovation/>.

For additional questions, email rutgershealthadvancement@rutgersfoundation.org.

We thank all our donors for their generous support.



OUR TEAM



Bishr Omary
Senior Vice Chancellor for
Academic Affairs and
Research



Kathleen Scotto
Vice Chancellor for Research and
Research Training & Vice Dean, School
of Graduate Studies



Shawna Hudson
Vice Chancellor for Dissemination
and Implementation Science



Adrienne Ettinger
Chief of Staff for Research



Janet Alder
Assistant Vice Chancellor for
Postdoctoral Affairs & Assistant Dean,
School of Graduate Studies



Najwa Borkadi
Executive Director for Research
Business Development



David Foran
Chief Research Informatics Officer



Natalie Bruiners
Senior Scientific Writer



Neil Grant
Director of Special Projects



Vickie Cadestin
Project Manager



Carlos Storck-Martinez
Senior Data Analyst



Denisse Caban-Santiago
Executive Assistant



Nancy Frazier-Carden
Management Assistant



Office of the Senior Vice Chancellor for Academic Affairs and Research
<https://rutgershealth.org/academic-affairs-research/office-research>

Rutgers, The State University of New Jersey
Stanley S. Bergen Building
65 Bergen Street
Newark, NJ 07107